Daiichi Sankyo Submits WelChol sNDA For Diabetes Indication
If approved, WelChol would be the first LDL-lowering therapy also approved for improving glycemic control.
If approved, WelChol would be the first LDL-lowering therapy also approved for improving glycemic control.